Back to top

Image: Bigstock

Hims & Hers Expanding Partnerships to Build a Global Health Ecosystem

Read MoreHide Full Article

Key Takeaways

  • HIMS relies on 1,500 providers and tech services to scale high-quality telehealth consultations.
  • Hims & Hers partners with health systems like Mount Sinai to enhance care without financial incentives.
  • HIMS expands globally via ZAVA acquisition and a 2026 Canada launch aligned with semaglutide access.

The renowned health and wellness platform, Hims & Hers Health, Inc.’s (HIMS - Free Report) partnerships and ecosystem strategy play a central role in its growth and international expansion. The company relies heavily on affiliated medical groups and licensed providers, which form the foundation of its telehealth operations. Nearly 1,500 providers are integrated into the platform, enabling patients to access timely, high-quality consultations and personalized treatment plans. Hims & Hers supports these groups through administrative and technology services but maintains provider independence in clinical decision-making, ensuring medical integrity while scaling access to care.

Hims & Hers has also forged partnerships with major U.S. health systems such as Ochsner, Mount Sinai and Hartford Healthcare. These collaborations enhance customer experience by providing access to in-person care when needed, complementing the digital platform. Notably, these arrangements do not involve financial incentives but rather strengthen continuity of care and expand Hims & Hers’ integration within traditional healthcare. On the pharmacy side, HIMS operates its own vertically integrated facilities while maintaining agreements with partner pharmacies like Curexa and ITC Compounding Pharmacy, ensuring flexibility and scale in prescription fulfillment.

Globally, Hims & Hers is extending its ecosystem through strategic acquisitions and market entries. The acquisition of ZAVA, a European digital health platform, significantly expanded its presence in the U.K., Germany, France and Ireland. Building on this, HIMS announced its planned 2026 entry into Canada, timed with the availability of generic semaglutide, aiming to deliver affordable, holistic weight-loss care. These moves illustrate how Hims & Hers combines organic growth with targeted partnerships and acquisitions to establish a global digital health footprint, uniting providers, pharmacies and international healthcare systems under its expanding ecosystem.

LFMD & AMWL’s Collaborations Driving Scalable Digital Care Ecosystems

LifeMD, Inc. (LFMD - Free Report) builds its ecosystem through contractual arrangements with affiliated professional entities, enabling physicians, nurse practitioners and behavioral health providers to deliver clinical services exclusively via the LifeMD platform. LifeMD further integrates with national laboratories for diagnostics, partner pharmacies for prescription fulfillment and technology providers supporting telehealth operations. These collaborations ensure LifeMD maintains scalability, compliance and continuity of care while broadening its digital health ecosystem.

American Well Corporation (AMWL - Free Report) , popularly known as Amwell, advances its partnerships and ecosystem strategy through long-term collaborations with more than 55 health plans, 100 health systems and 2,000 hospitals, covering over 80 million lives. Amwell integrates its Converge platform into partner systems, enabling hybrid care delivery and digital-first programs. Additionally, Amwell’s ecosystem includes collaborations with employers, technology partners and device makers, reinforcing its role as a digital infrastructure provider across the U.S. healthcare landscape.

HIMS’ Price Performance, Valuation and Estimates

Shares of Hims & Hers have gained 110.2% year to date, outperforming the industry’s growth of 24.7%.

Zacks Investment Research
Image Source: Zacks Investment Research

HIMS’ forward 12-month P/S of 4.1X is lower than the industry’s average of 5.8X, but is higher than its three-year median of 2.4X. It carries a Value Score of D.

Zacks Investment Research
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 122.2% improvement from 2024.

Zacks Investment Research
Image Source: Zacks Investment Research

Hims & Hers stock currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


American Well Corporation (AMWL) - free report >>

Hims & Hers Health, Inc. (HIMS) - free report >>

LifeMD, Inc. (LFMD) - free report >>

Published in